Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society's Young Investigator Award at 40th Annual Meeting and Exposition
Bridgewater, New Jersey, July 18, 2013—Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing patient-optimized oral products utilizing its proprietary pharmaceutical technologies and development expertise, today announces its co-sponsorship of Controlled Release Society's Young Investigator Award. The award will be presented during the 40th Annual Meeting & Exposition of the Controlled Release Society July 21 - 24, 2013 in Honolulu, Hawaii.
2013 CRS Young Investigator Award
|
Aptalis Pharmaceutical Technologies, co-sponsor of the 2013 CRS Young Investigator Award, joins the Controlled Release Society in recognizing Ali Khademhosseini, MASc, PhD, Associate Professor of Medicine at Harvard-MIT's Division of Health Sciences and Technology and Harvard Medical School, Brigham & Women's Hospital and Associate Faculty at the Wyss Institute. Dr. Khademhosseini is developing micro- and nanoscale technologies to control cellular behavior for tissue engineering and drug delivery applications. He has published over 220 peer-reviewed papers and 160 abstracts. He has received numerous awards, including the NSF Career, PECASE, ONR Young Investigator, Colburn, Y. C. Fung, IEEE EMBS, and IEEE Nanotechnology awards. He received his PhD in bioengineering from MIT, and master's and bachelor's degrees from University of Toronto, both in chemical engineering. |
The Young Investigator Award recognizes a CRS member, who has made outstanding contributions in the science of controlled release, and who is 40 years of age or younger in the year the award is presented.
About Aptalis Pharmaceutical Technologies
Aptalis Pharmaceutical Technologies is a trusted oral drug delivery partner for overcoming even the most demanding delivery challenges, using proprietary technologies and development expertise for bioavailability enhancement, custom release profiles and taste-masking for dosage forms including orally disintegrating tablets, resulting in patient-optimized products. Aptalis provides flexible and tailored co-development and product out-licensing deals to enable partners to successfully bring IP-protected, value-added Rx and OTC products to market. It has multinational and integrated R&D and manufacturing teams and facilities in the U.S. and Europe, to offer global solutions to companies in various regions around the world. For more information about Aptalis Pharmaceutical Technologies, visit www.aptalispharmatech.com.
About Aptalis Pharma
Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis, formed from the combination of Axcan Pharma and Eurand, has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, PANZYTRAT® and SALOFALK®. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.aptalispharma.com.
Media Contact:
Erin O'Brien, Director of Marketing
Aptalis Pharmaceutical Technologies
908-927-9600